Condensed Consolidated Statements of Operations and Comprehensive Loss (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2012	Mar. 31, 2011
Revenue	$ 24,519	$ 18,548
Cost of goods sold	5,403	4,373
Gross profit	19,116	14,175
Operating expenses:
Research and development	3,761	4,006
Clinical and regulatory affairs	1,402	917
Marketing and sales	13,547	10,098
General and administrative	4,080	3,579
Distribution contract termination	0	400
Total operating expenses	22,790	19,000
Loss from operations	(3,674)	(4,825)
Other income (expense):
Interest income	3	10
Interest expense	(7)	(7)
Other expense	(1)	27
Change in fair value of contingent consideration related to acquisition (Note 9)	(12,450)	0
Total other expense	(12,455)	30
Net loss before income tax expense	(16,129)	(4,795)
Net loss	(16,703)	(4,795)
Income tax expense	(574)	0
Basic and diluted net loss per share	$ (0.29)	$ (0.09)
Shares used in computing basic and diluted net loss per share	57,620	55,906
Comprehensive loss:
Net loss	(16,703)	(4,795)
Foreign currency translation adjustment	5	0
Comprehensive loss	$ (16,698)	$ (4,795)